Cargando…
Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope
Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug ta...
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183299/ https://www.ncbi.nlm.nih.gov/pubmed/37197377 http://dx.doi.org/10.1093/rap/rkad039 |
| _version_ | 1785041926479675392 |
|---|---|
| author | Zhao, Sizheng Steven Harrison, Stephanie R Chan, Antoni Clarke, Nick Davis, Charlotte Eddison, Joe Gregory, William J Jones, Gareth T Marzo-Ortega, Helena Murphy, Daniel J Sandhu, Virinderjit Sengupta, Raj Siebert, Stefan Thompson, Ben Webb, Dale Yates, Max Gaffney, Karl |
| author_facet | Zhao, Sizheng Steven Harrison, Stephanie R Chan, Antoni Clarke, Nick Davis, Charlotte Eddison, Joe Gregory, William J Jones, Gareth T Marzo-Ortega, Helena Murphy, Daniel J Sandhu, Virinderjit Sengupta, Raj Siebert, Stefan Thompson, Ben Webb, Dale Yates, Max Gaffney, Karl |
| author_sort | Zhao, Sizheng Steven |
| collection | PubMed |
| description | Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities. |
| format | Online Article Text |
| id | pubmed-10183299 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101832992023-05-16 Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope Zhao, Sizheng Steven Harrison, Stephanie R Chan, Antoni Clarke, Nick Davis, Charlotte Eddison, Joe Gregory, William J Jones, Gareth T Marzo-Ortega, Helena Murphy, Daniel J Sandhu, Virinderjit Sengupta, Raj Siebert, Stefan Thompson, Ben Webb, Dale Yates, Max Gaffney, Karl Rheumatol Adv Pract Guideline Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities. Oxford University Press 2023-05-15 /pmc/articles/PMC10183299/ /pubmed/37197377 http://dx.doi.org/10.1093/rap/rkad039 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Guideline Zhao, Sizheng Steven Harrison, Stephanie R Chan, Antoni Clarke, Nick Davis, Charlotte Eddison, Joe Gregory, William J Jones, Gareth T Marzo-Ortega, Helena Murphy, Daniel J Sandhu, Virinderjit Sengupta, Raj Siebert, Stefan Thompson, Ben Webb, Dale Yates, Max Gaffney, Karl Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope |
| title | Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope |
| title_full | Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope |
| title_fullStr | Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope |
| title_full_unstemmed | Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope |
| title_short | Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope |
| title_sort | treatment of axial spondyloarthritis with biologic and targeted synthetic dmards: british society for rheumatology guideline scope |
| topic | Guideline |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183299/ https://www.ncbi.nlm.nih.gov/pubmed/37197377 http://dx.doi.org/10.1093/rap/rkad039 |
| work_keys_str_mv | AT zhaosizhengsteven treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT harrisonstephanier treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT chanantoni treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT clarkenick treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT davischarlotte treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT eddisonjoe treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT gregorywilliamj treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT jonesgaretht treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT marzoortegahelena treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT murphydanielj treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT sandhuvirinderjit treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT senguptaraj treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT siebertstefan treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT thompsonben treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT webbdale treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT yatesmax treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope AT gaffneykarl treatmentofaxialspondyloarthritiswithbiologicandtargetedsyntheticdmardsbritishsocietyforrheumatologyguidelinescope |